| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000006002 |
| Receipt No. | R000007101 |
| Official scientific title of the study | Effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI |
| Date of disclosure of the study information | 2011/07/19 |
| Last modified on | 2018/09/05 (Ver. 2) |
| Basic information | ||
| Official scientific title of the study | Effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI | |
| Title of the study (Brief title) | Effectiveness of intracoronary bolus abciximab application for No-Reflow or Slow flow phenomenon during PCI | |
| Region |
|
|
| Condition | ||
| Condition | Patients suffer from No-Reflow or Slow flow phenomenon during PCI | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the effectiveness of intracoronary bolus abciximab application for patients who suffer from No-Reflow or Slow flow phenomenon during PCI |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | Pragmatic |
| Developmental phase | Not applicable |
| Assessment | |
| Primary outcomes | Rate of attrition of ST elevation ratio :Comparison between at 30 minutes after PCI and at the time of maximum ST elevation |
| Key secondary outcomes | 1. Rate of ST re-elevation after intracoronary bolus application of drug(s)
2. TIMI flow after PCI 3. Myocardial blush grade after PCI 4. Maximum value of CPK/CPK-MB after PCI 5. MACCE at 30 days / 1 year after PCI 6. Existence or nonexistence of serious hemorrhagic complication 7. Angiographical phenomenon at follow-up CAG |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Double blind -all involved are blinded |
| Control | Placebo |
| Stratification | YES |
| Dynamic allocation | NO |
| Institution consideration | Institution is considered as a block. |
| Blocking | NO |
| Concealment | Numbered container method |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Abciximab (+) | |
| Interventions/Control_2 | Abciximab (-) | |
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. Patients with coronary artery disease
2. Patients who take aspirin and thienopyridine 3. Informed consent was obtained from patients |
|||
| Key exclusion criteria | 1.with hemorrhagic diathesis and/or hypercoagulability
2.under emergent PCI 3.received thrombolytic therapy before PCI 4.more than twice the value of standard CPK and CPK-MB 5.be pregnant or nursing 6.with unprotected LMT disease |
|||
| Target sample size | 30 | |||
| Research contact person | |
| Name of lead principal investigator | Kazuaki Mitsudo |
| Organization | Kurashiki Central Hospital |
| Division name | Department of Cardiology |
| Address | Kurashiki city miwa 1-1-1, Okayama, Japan |
| TEL | 086-422-0210 |
| Public contact | |
| Name of contact person | Daiji Hasegawa |
| Organization | Kurashiki Central Hospital |
| Division name | Department of Cardiology |
| Address | Kurashiki city miwa 1-1-1, Okayama, Japan |
| TEL | 086-422-0210 |
| Homepage URL | |
| dh10969@kchnet.or.jp | |
| Sponsor | |
| Institute | Department of Cardiology, Kurashiki Central Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Department of Cardiology, Kurashiki Central Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 倉敷中央病院 |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000007101 |